JOHNSON & JOHNSON
Company Snapshot
Company Overview
Johnson & Johnson is involved in the research, development, manufacturing, and sale of pharmaceuticals and medical devices. In September 2022, Johnson & Johnson renamed its consumer health division Kenvue and announced plans to spin off the unit. In May 2023, Kenvue went public on the New York Stock Exchange, trading under the ticker symbol KVUE.
After the consumer health business split, Johnson & Johnson Services Inc. is organized into two segments: Innovative Medicine and MedTech. The MedTech segment (formerly known as Medical Devices) includes a wide range of products used in Interventional Solutions, Orthopedics, Surgery, and Vision categories.
Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceutical Companies) offers diverse portfolios across multiple therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. It is a leading provider of gastroenterology drugs, including IBD therapies. It markets its products in over 175 countries and has approximately 138,100 employees worldwide.
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
JOHNSON & JOHNSON In News
Company's Business Segments
- Innovative Medicine : Immunology, Neuroscience, Infectious Diseases, Cardiovascular and Metabolism, Pulmonary Hypertension.
- MedTech : MEdTech segment inclues Surgery, Orthopaedics, Interventional Solutions, Vision
Applications/End User Industries
- Surgeons
- Orthopedic Specialists
- Ophthalmologists
- General Surgeons
- Orthopedic Surgeons
- Cardiothoracic Surgeons
- Neurosurgeons
- Pulmonary Arterial Hypertension
- Gynecologists
- Obstetricians
- Rheumatologists
- Pediatricians
- Hematologists
- Pain Management Specialists
- Immunology-Related Medications
- Biologic Therapies
- Antifungal Medications
- Cardiovascular Diseases
- Dermatologists